Investor Presentation Full Year 2021

38 B-cell function Investor presentation Full year 2021 Diabetes is a chronic disease requiring treatment intensification over time Diet and exercise Time Distribution of patients and value across treatment classes 100% OAD GLP-1 4% 16% 80% 44% 17% 1% 60% 25% 18% Insulin 40% 4% 8% 20% 37% 26% 0% Patients Insulin GLP-1 Inj. DPP-IV Value Oral GLP-1 Trad. OAD SGLT-2i Note: Patient distribution across treatment classes is indicative and based on data for the USA, Germany, France. Other OADs cover: metformin, sulfonylurea, thiazolidinediones. Source: IQVIA PharMetrix claims data, IQVIA disease analyser, IQVIA MIDAS; value figures based on IQVIA MAT, Nov 2021 OAD: Oral anti-diabetic Novo NordiskⓇ

View entire presentation